ArticleCancer letters2018

Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.

Hui Lyu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.